Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trial of YH25448 in Patients With EGFR Mutation Positive Advanced NSCLC

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed diagnosis of NSCLC with single activating EGFR mutations.~* Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1 with no deterioration over the previous 2 weeks and a minimum life expectancy of 3 months.~* At least one measurable extracranial lesion, not previously irradiated and not chosen biopsy during the study screening period.~* Prior to enrolling in the study, patients must have central confirmation of T790M+ mutation status from a sample taken after documented progression on the EGFR-TKIs therapy according to cohort.~Exclusion Criteria:~* Spinal cord compression.~* Brain metastases with symptomatic and/or requiring steroid for at least 2 weeks prior to start of study treatment.~* Known intracranial hemorrhage which is unrelated to tumor.~* Central Nervous System (CNS) complications that require urgent neurosurgical intervention (e.g. resection or shunt placement).~* Leptomeningeal metastasis prior to study treatment.~* Past medical history of interstitial lung disease (ILD), drug-induced ILD, radiation pneumonitis which required steroid treatment, or any evidence of clinically active ILD.~* Any cardiovascular disease as followed.~  * History of symptomatic congestive heart failure (CHF) or serious cardiac arrhythmia requiring treatment~ * History of myocardial infarction or unstable angina within 6 months of the first dose of study treatment~ * Left ventricular ejection fraction (LVEF) \< 50%

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- YH25448 (Type: EXPERIMENTAL): * Dose Escalation Phase: Consists of 7 Cohorts~* Dose Expansion Phase: Consists of 5 Cohorts~* Dose Extension Phase: Consists of 2 Cohorts

Based on this trial design, predict the completion outcome and termination type (if applicable).